FRANKFURT (dpa-AFX Broker) - Shares in Evonik rose on Tradegate on Monday following the chemical company's outlook. They rose by 1.4 percent to 17.40 euros.

Although the MDax company does not expect a rapid recovery in the current year after a difficult 2023, both the targets for the first quarter and the full year are close to consensus estimates, commented JPMorgan analyst Chetan Udeshi.

According to him, this should provide confidence. He also praised - as did analyst firm Jefferies - the strong free cash inflow in the fourth quarter of 2023, "which was much better than expected"./ck/zb

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------